Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HS-10374 versus placebo in adults with moderate-to-severe plaque psoriasis
ChiCTR2400091645Phase 3Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing HS-10374 12 mg QD with Placebo QD (2 arms). Primary endpoints: PASI 75 response rate and sPGA 0/1 response rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
HS-10374
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2400091645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091645.